After his training as an MD, Stephan obtained his PhD in Medical Physiology with a thesis on a cardiovascular topic. From 2008 onwards, he shifted his focus to oncology as a resident in pathology. He actively participated in multidisciplinary team meetings for general oncology and head & neck cancer. In 2009 he started his career in the pharmaceutical industry as a Medical Monitor at Wyeth (now Pfizer), where he was responsible for studies in breast cancer and lymphomas. Later, he took over project management responsibilities for several Phase I-III oncology studies in breast cancer, leukemia, lung cancer and solid tumors when working as Clinical Project Manager Oncology at Boehringer Ingelheim. Before joining SMS-oncology in 2016, he worked as safety physician/medical lead and protocol author at Julius Clinical for studies in various therapeutic areas, including Phase I oncology. Throughout his career in the pharmaceutical and CRO arena, he gained strong experience in clinical oncology drug development and operational insights. At SMS-oncology, Stephan took the position of Director Medical Affairs where he heads the Medical Affairs department and is currently responsible for thorough medical reviews and providing expert advice.